Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
- Home
- News and Insights
- Insights
- New Securities Law Disclosures in 2004 Forms 10 K 10 Q and 8 K and Proxy Statement
New Securities Law Disclosures in 2004: Forms 10-K, 10-Q and 8-K and Proxy Statement
January 12, 2004, Covington Advisory
11/07/2013
WASHINGTON, DC, November 7, 2013 — Salix Pharmaceuticals, Ltd., and Santarus, Inc. announced today that the companies have entered into a merger agreement where Salix will acquire all of the outstanding stock of Santarus for $32 in cash per share, for a total value of approximately $2.6 billion. Covington & Burling LLP is advising Salix on both the acquisition ...
November 1, 2004, Covington Advisory
August 2004, Benefits Practice Center, Executive Compensation Library, Journal Reports: Law and Policy (BNA)